As a prerequisite to nonviral gene therapy approaches of ovarian carcinoma, we evaluated the possibility of transfecting established tumor cell lines (SKOV3, IGROV1) as well as primary mesothelial and tumor cells by various polyethylenimine (PEI) derivatives. Several PEI-based vectors were able to effectively transfect these cells, as shown by high luciferase expression levels (10 8 to 10 9 relative light units per milligram of cell protein) that corresponded with 25-50% of green fluorescent protein-positive cells after 24 hours. However, unpredictable differences were observed among the vectors and cell types that a posteriori justified the screening procedure. We also showed that cells that were not transfected after the first experiment remained transfectable in a subsequent transfection experiment to a level similar to that of the initial population. This experiment does not support the emergence of a transfection-resistant cell population and opens the door to multiple therapeutic gene deliveries. Although efficacy and cell targeting still remain to be improved, PEI derivatives appear to be promising molecules for the development of nonviral gene therapy of ovarian carcinoma. Cancer Gene Therapy (2000) 7, 644 -652
D
espite recent advances in chemotherapy, ovarian cancer remains the leading cause of death due to gynecological malignancy in Western countries. Late tumor detection with peritoneal dissemination as well as chemoresistance acquisition after initial chemotherapy are responsible for the poor prognosis of ovarian cancer. The overall survival rate after 5 years does not exceed 25%. Gene therapy may represent an attractive alternative to the classical treatments, and numerous approaches show the potential interest in this novel therapy for the treatment of ovarian carcinoma (reviewed in Refs. [1] [2] [3] . Several protocols are based on the use of suicide genes such as the herpes simplex thymidine kinase gene 4 -8 or on the re-establishment of wild-type p53 function. 9 Moreover, in the majority of cases, ovarian cancer dissemination is confined to the peritoneal cavity, allowing local administration of the transgene. Intraperitoneal delivery reduces general toxicity compared with systemic delivery and increases the transgene concentration around the tumor.
Synthetic vectors are essentially based on the condensation of DNA by cationic lipids (lipoplexes) or polymers (polyplexes). 10 These complexes are able to effectively transfect animal cells in vitro, although they remain well behind viral vectors in terms of the number of genes needed to transfect a cell. However, nonviral vectors present an excellent safety profile, are simple and easier to produce than viral vectors, and are straightforward to use in a clinical environment. Polyethylenimine (PEI) derivatives are effective DNA vectors both in vitro 11, 12 and in vivo, [13] [14] [15] mainly as a consequence of their endosome-swelling properties. 16 Several topologies and molecular masses are available, including a linear polymer (linear PEI (L-PEI), molecular mass of 22 kDa, ExGen 500) and a branched polymer (branched PEI (B-PEI), molecular mass of 25 kDa); the structures of each polymer are shown in Figure 1 . Various ligands, such as saccharides, 17, 18 peptides, 19 or proteins, 20 have been conjugated to PEI to achieve receptor-mediated cell entry of DNA.
Gene transfer efficacy with nonviral vectors, in contrast to viral vectors, remains poorly studied in ovarian carcinoma. Our purpose here was to evaluate PEIs and their derivatives for gene delivery to ovarian cancer cells. Using established tumor cell lines (SKOV3 and IGROV1) as well as primary cultures of mesothelial and tumor cells, we found that several PEI derivatives were able to efficiently transfect our cellular models, although large differences were observed among the vectors and cells.
MATERIALS AND METHODS

Chemicals
B-PEI (mean molecular mass of 25 kDa, average degree of polymerization of 580 assuming a molecular mass of 43 Da for the repeating unit) and sodium cyanoborohydride were obtained from Aldrich (St. Quentin Fallavier, France). L-PEI (linear polymer, mean molecular mass of 22 kDa, ExGen 500) and 5-bromo-4-chloro-3-indolyl-␤-D-galactosidase were obtained from Euromedex (Souffelweyersheim, France). Linear tetragalactose (Gal ␣3 Gal ␤4 Gal ␣3 Gal (Gal 4 )) and tetraglucose (Glc ␣4 Glc ␣4 Glc ␣6 Glc, (Glc 4 )) were supplied by Dextra Laboratories (Reading, UK). Sephadex G-25 fine columns were obtained from Fluka (St. Quentin Fallavier, France).
Preparation of glycosylated PEI conjugates
B-PEI or L-PEI were glycosylated by reductive amination in the presence of sodium cyanoborohydride. 17 For the polyethylenimineose conjugates, linear tetragalactose (Gal 4 ) or tetraglucose (Glc 4 ) (5 mol) and sodium cyanoborohydride (25 mol) were added to PEI (100 mol of monomer, 100 L of 1 M stock solution (pH 7.0)) in 0.9 mL of borate buffer (0.2 M, pH 8.2) and left for 96 hours at room temperature with stirring. Low molecular mass compounds were removed by gel filtration on a Sephadex G-25 fine column (12.5 ϫ 450 mm) in 0.15 M NaCl. The average number of glycosyl residues per PEI molecule was determined using the resorcinol/sulfuric acid micromethod. 21 The extent of grafting was expressed as the percentage of glycosyl residues per amino group of PEI and was found to be 5%. The polymer concentration was determined by the trinitrobenzene sulfonic acid assay for B-PEI and by the ninhydrin assay for L-PEI.
Cell lines
The cell lines IGROV1 and SKOV3 were established from a human ovarian adenocarcinoma. 22, 23 IGROV1 was provided by Dr. J. Bénard (Institut Gustave Roussy, Villejuif, France), and SKOV3 was obtained from the European Collection of Animal Cell Cultures (Cerdic, Nice, France). An IGROV1 subline (IGROV1-R10) presenting a 10-fold resistance to cisplatin compared with the parental cell line was established by successive exposures to increasing doses of cisplatin, as described previously. 24 Cells were grown in RPMI 1640 medium (Life Technologies, Lyon, France) supplemented with 10% fetal calf sera (FCS) (Life Technologies), 2 mM glutamine (Life Technologies), 33 mM sodium bicarbonate, 20 mM N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid, 100 U/mL penicillin (Life Technologies), and 100 g/mL streptomycin (Life Technologies). Cells were maintained at 37°C in a 5% CO 2 humidified atmosphere and were split twice per week by trypsinization.
Primary tumor cells
Ascitic fluids and peritoneal tumor nodes were collected from patients during normal debulking surgery. Isolated cells obtained either by mechanic and enzymatic (trypsine-versene, Life Technologies) dissociation of tumor nodes or by centrifugation of ascitic fluids were resuspended in RPMI 1640 medium (Life Technologies) supplemented with 10% FCS (Life Technologies), 2 mM glutamine (Life Technologies), 33 mM sodium bicarbonate, 20 mM N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid, 100 U/mL penicillin (Life Technologies), and 100 g/mL streptomycin (Life Technologies). Cells were distributed at a high density in 24-well microplates and maintained at 37°C in a 5% CO 2 humidified atmosphere until an adherent monolayer of growing cells became visible (24 -48 hours). After several washes, transfection was assessed as described below. These primary cultures were named WH.01 and SCH.01.
Plasmids
Transfections were performed using either luciferase, lacZ gene, or green fluorescent protein (GFP) reporter genes. pCMVLuc was provided by Dr. B. Demeneix (Museum d'Histoire Naturelle, Paris, France); pCMVLacZ and pCM-VEGFP-C3 were obtained from Clontech (Palo Alto, Calif). 
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Complex formation and transfection
Transfections were carried out in triplicate with 5 ϫ 10 4 cells/well that were previously seeded in 24-well tissue culture plates and grown for 24 hours at 37°C. DNA (6 g of plasmid for a triplicate experiment) and the desired amount of PEI or PEI conjugate were diluted separately in 150 L of 0.15 M NaCl (for the B-PEI and its derivatives) or in 5% glucose solution (for L-PEI and its derivatives). After 10 minutes, PEI was added to the DNA and the solution was homogenized and left for 10 minutes at room temperature. The polycation/DNA complexes were added to the cells (100 L per well), and the plates were incubated at 37°C in an humidified atmosphere containing 5% CO 2 . Cells were transfected in the absence of sera for 2 hours, and 10% FCS was added thereafter.
Luciferase assay
Cells were lysed at 24 hours posttransfection, and luciferase gene expression was quantified using a commercial kit (Promega, Cergy Pontoise, France) and a luminometer (Mediators PhL, Wien, Austria). Results are expressed as relative light units (RLUs) integrated over 10 seconds per milligram of cell protein lysate (RLU/mg protein) using the bicinchoninic acid assay (Pierce, Paris, France). The error bars in Figures 2, 3, 6, and 7, represent SDs derived from triplicate transfection experiments.
Detection of GFP
Cells were analyzed by flow cytometry. Transfected cells were harvested by trypsinization and washed with phosphate-buffered saline. Flow cytometric analysis was performed with a FACStar Plus (Becton Dickinson, San Jose, Calif) using an argon laser (400 molecular mass power at a wavelength of 488 nm). Sort windows were used on forward and side scatter to eliminate debris. Granulation, size, and fluorescence (emission 515 nm) intensity were recorded at a rate of ϳ800 cells per second. Data were analyzed using CellQuest software (Becton Dickinson) and were expressed as mean fluorescence and/or as the percentage of GFP-positive cells. Cell sorting was performed on the same apparatus using the same gates for GFP-positive or GFP-negative cells.
RESULTS
Optimal transfection conditions using B-PEI and L-PEI
Transfection with nonviral vectors relies on the cationic surface charge of the complexes. 25 Therefore, we determined the optimal PEI amine (N) per DNA phosphate (P) ratio (N/P ratio) for transfection of SKOV3 ovarian tumor cells by B-PEI and L-PEI. The amount of plasmid DNA was kept constant at 2 g; smaller amounts led to decreased luciferase levels, whereas larger amounts did not lead to a significant increase (data not shown). Complexes were prepared in 0.15 M NaCl or in 5% glucose, respectively, considering the favorable physicochemical properties of B-PEI and L-PEI in these media. 15, 26 In both cases, the size of the complexes decreased when the N/P ratio was increased. The size of the L-PEI complexes, however, was much smaller than that of B-PEI complexes, even at a low N/P ratio. Both PEIs led to efficient transfection of SKOV3 cells at a N/P ratio of Ͼ5 (Fig 2A) . However, L-PEI-mediated transfection of SKOV3 cells was associated with cell detachment at N/P ratios of Ͼ10, and cell death occurred thereafter. In contrast, B-PEI showed no visible toxicity. 4Ј,6-diamidino-2-phenylindole allows visualization of both nuclear morphology and of the distribution of DNA-containing complexes under the fluorescence microscope. Figure 2B shows that B-PEI complexes form very large aggregates on the cells at an N/P ratio of 5; these aggregates presumably reach the cell by sedimentation. Although they are of micrometric size, the aggre- gates enter cells because high levels of transfection are obtained. At an N/P ratio of 10, B-PEI resulted in small particles with DNA that appeared evenly distributed in/onto cells. Similar observations were made with L-PEI at N/P ratios of 5 and 10. Taking into account the transfection efficiency, toxicity, and size of the complexes, we decided to use L-PEI at an N/P ratio of 5 and B-PEI at an N/P ratio of 10.
Transfection of IGROV1 and SKOV3 cells
The luciferase reporter gene showed that L-PEI efficiently transfected (10 9 RLU/mg protein) both IGROV1 and SKOV3 cell lines (Fig 3) . Surprisingly, the transfection level never exceeded 10 6 RLU/mg protein with IGROV1 cells when B-PEI was used. To obtain a more precise view of the level of transfection, we used the GFP reporter gene system, which allows quantitative analysis of transfected cells by flow cytometry as well as their visualization under the microscope. For SKOV3 cells, L-PEI and B-PEI transfected 45% and 54% of the cells, respectively (Fig 4A) . IGROV1 cells were slightly less transfected than SKOV3 cells when L-PEI was used (18%), whereas B-PEI showed no measurable transfection (Fig 4B) . Visual observation of GFP-transfected SKOV3 cells on glass coverslips confirmed that the expression was very heterogeneous (data not shown), as was expected from the 2-order-of-magnitude fluorescence spread observed by flow cytometry. These observations were also confirmed with the more classical ␤-galactosidase cytochemical analysis (data not shown).
Cell-sorting experiments
Because of therapeutic considerations, we wondered why at least 50% of ovarian cancer cells remained untransfected irrespective of the vector used. Cell sorting was used to determine whether transfection was cell cycle-dependent or whether a subpopulation was resistant to transfection. The non-GFP-expressing SKOV3 cells were harvested 24 hours after transfection with L-PEI/GFP DNA complexes by way of the cell sorter, as described in Materials and Methods. After the cells recovered a normal growth pattern (6 days), they were transfected with either L-PEI or B-PEI. The results in Figure 5 show that 14% of the daughter cells of cells not expressing at 24 hours posttransfection actually expressed GFP 1 week later. Furthermore, these cells remained transfectable to an extent similar to naive cells (ϳ45% with L-PEI).
Receptor-mediated gene transfer
Apart from heparan sulfate proteoglycans, which act as a receptor for cationic vectors in general, 27 less ubiquitous cell surface molecules have also been targeted as a means of carrying PEI-condensed DNA into cells. [17] [18] [19] [20] Among the ligands, we chose to test both an Arg-GlyAsp (RGD) peptide derivative that binds certain integrins and a galactosylated derivative that is able to trigger endocytosis into the corresponding lectin-expressing cells.
B-PEI-Gal 4 led to improved transfection efficiency in both cell lines compared with B-PEI (60-fold in IGROV1 and 20-fold in SKOV3) as shown in Figure 6 . However, the most drastic effect was observed for both cell lines with RGD peptides conjugated to B-PEI. Indeed, the transfection levels reached 10 8 RLU/mg of protein for IGROV1 and 10 9 RLU/mg of protein for SKOV3. Compared with the plain B-PEI polymer backbone, these levels represent a 1300-fold increase for IGROV1 and a 10-fold increase for SKOV3 (Fig 6) .
Ex vivo transfection of primary mesothelial and ovarian tumor cells
We subsequently transfected a primary culture of mesothelial cells (WH.01) obtained from a patient's ascite sample. B-PEI appeared to be the least efficient vector, as luciferase activity remained below 10 7 RLU/mg of protein even with 2 g of DNA per well. We also tested L-PEI and the galactosylated derivatives of L-PEI and B-PEI. In all cases, a level of luciferase activity of 3-9 ϫ 10 7 RLU/mg protein was obtained (Fig 7A) . L-PEI was toxic on these cells when 2 g of DNA per well was used. Reducing the amount of DNA from 2 g/well to 1 g/well led to a drastic decrease in transfection (10-to 30-fold compared with the levels obtained with 2 g/well).
SCH.01 cells were obtained from the peritoneal nodes of a patient with advanced stage ovarian tumor as described in Materials and Methods. Both cellular and nuclear morphologies suggested that the population was composed mainly of tumor cells. The histogram of DNA content obtained by flow cytometry was in agreement with these observations, with Ͼ80% of the cells being tetraploid (data not shown). This cell population was transfected 24 hours after plating, and the levels of luciferase activity obtained with various PEI derivatives reached 10 8 to 10 9 RLU/mg protein (Fig 7B)  ( i.e., no significant differences were observed among the vectors).
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DISCUSSION
Peritoneal carcinomatosis represents a common outcome of many carcinomas, such as colon, pancreatic, cervical, mesothelial, and ovarian cancers. This local extension of the disease can lead to death on its own. In ovarian carcinoma, complete surgical tumor exeresis is generally impossible, partly because of the presence of microperitoneal grafts. Paradoxically, a satisfactory response rate to conventional platinum chemotherapy can be observed, although chemoresistance-associated relapse frequently occurs in the following months. This explains the poor survival rate (25-30% after 5 years) of patients with advanced stage disease. Various therapeutic strategies can be envisaged to overcome chemoresistance, among which the development of orthogonal treatments such as gene therapy appear to be the most attractive.
We investigated the transfection of ovarian cancer cells by nonviral vectors using various PEI derivatives and both established cell lines and primary tumor cells. Although we observed large variations in the transfection levels with cell type and vector, our results show that some of the PEI vectors tested allow efficient transfection of all ovarian tumor cells, as demonstrated by the overall gene expression level measured with the luciferase reporter gene as well as by the percentage of transfected cells. L-PEI (ExGen 500) consistently appeared to be the most versatile and efficient vector, because it led to high luciferase expression levels in all of the models we used, including primary cells, which are known to be more difficult to transfect.
As far as therapy is concerned, the percentage of transfected cells should be a more relevant factor than the overall expression level. GFP reporter gene transfection showed that 20 -55% of the cells expressed the transgene at 24 hours after transfection with L-PEI. In contrast, large differences were observed among the cell lines using B-PEI. Indeed, although Ͼ50% of SKOV3 cells were transfected, IGROV1 cells were essentially resistant to transfection. The highest transfection level never exceeded 55% of the cells. The reason for such a plateau remains to be determined. However, the finding that as many as 13% of cells originating from those that did not express the reporter gene after 24 hours do express it after 7 days raises an interesting possibility. The nuclear membrane is the major intracellular barrier to transfection, 27 and cells that did not divide during incubation with the reporter gene are less likely to overcome this barrier. A doubling time of ϳ24 hours and 50% cells transfected after 24 hours is thus compatible with a scenario in which most cells may go through the transfected state with time, with some being transfected later while others eventually disappear as a consequence of toxic side effects of transgene expression. This possibility is reinforced by the fact that the nonexpressing cells remained transfectable to a degree that was similar to that for the initial population. This is a major finding of this work, because it implies that PEI-mediated transfection of a therapeutic gene does not select a resistant population of ovarian cancer cells, and thus opens the door to multiple runs of transgene delivery.
In vivo gene transfer efficiency could be increased as a result of more selective delivery. This is why we synthesized several derivatives of PEI, such as B-PEI-RGD and B-PEI-Gal 4. The ␣ v subunit of integrins, which binds RGD-containing sequences, has been shown to be systematically expressed in ovarian carcinoma, 28, 29 although the ␤-subunit partner may vary with the tumor differentiation grade. The use of B-PEI-RGD led to a 10-to 1300-fold increase in luciferase activity compared with B-PEI, depending upon the cell line. Neither the cell surface lectin distribution nor the substrate selectivity of our cells are known. However, we still decided to test the B-PEI-Gal 4 derivative, and a 10-to 60-fold increase in luciferase activity was observed in several cell types compared with B-PEI. Although the B-PEI-Gal 4 efficacy was higher than that of B-PEI, it generally remained lower than that of B-PEI-RGD. Taken together, these results suggest that derivatization of PEI leads to receptor-dependent gene delivery to ovarian carcinoma cells. This could be of particular interest in vivo for tumor targeting, although other considerations should then be taken into account as well. For example, the size of PEI/DNA complexes should be considered, because inaccurate predictions could be made from the extrapolation of cell culture transfection trends to in vivo gene delivery. Indeed, larger complexes transfect cell cultures better simply because of sedimentation, 12 whereas in vivo they may encounter severe size-restricted diffusion. 30 In summary, L-PEI and B-PEI-RGD allow effective transfection of all ovarian tumor cell lines tested, as shown by high overall luciferase expression levels and by high percentages of GFP-positive cells. They also lead to reasonably small complexes with plasmid DNA that eventually may diffuse away from the injection site in vivo. The ratio of transfected cells is compatible with antitumor strategies, 31 because it has been demonstrated that a bystander effect could eradicate a population of tumor cells in which only 10% of the cells were initially transfected. This is especially true in the case of suicide genes, 32, 33 where the transfer of soluble toxic metabolites through gap junctions occurs. 34 -36 Although efficacy and cell targeting still remain to be improved, PEI derivatives are promising molecules for the development of nonviral gene therapy of ovarian carcinoma. The validation of PEI-based suicide gene therapy in ovarian carcinoma is currently under investigation, and further studies will be necessary to evaluate the use of PEI derivatives for the in vivo transfection of peritoneal carcinomatosis nodes established in nude mice.
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